Arbutus Biopharma (ABUS) EBT (2013 - 2026)

Arbutus Biopharma has reported EBT for 14 years, with the latest figure at $169.7 million in Q1 2026.

• Quarterly EBT rose 791.81% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.0 million (up 307.63% YoY) and the FY2025 annual result came in at -$215.5 million, down 208.18% from the prior year.
• EBT grew to $169.7 million in Q1 2026 per ABUS's latest filing, from -$4.4 million in the prior quarter.
• Over five years, EBT peaked at $169.7 million in Q1 2026 and troughed at -$24.5 million in Q1 2025.
• A 5-year average of -$4.3 million and a median of -$17.1 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2026: EBT tumbled 44.32% in 2023, then soared 791.81% in 2026.
• Over 5 years, EBT stood at -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then surged by 32.8% to -$13.0 million in 2024, then soared by 65.86% to -$4.4 million in 2025, then jumped by 3929.84% to $169.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $169.7 million, -$4.4 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.